SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $21,000.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $7.00, for a total transaction of $21,000.00. Following the completion of the transaction, the insider owned 600,887 shares in the company, valued at approximately $4,206,209. This trade represents a 0.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.29, for a total transaction of $123,930.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total transaction of $69,200.00.
• On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $22,800.00.
• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total transaction of $38,221.81.

SOPHiA GENETICS Price Performance

Shares of NASDAQ SOPH traded up $1.02 during mid-day trading on Friday, reaching $7.71. 963,487 shares of the company were exchanged, compared to its average volume of 220,563. SOPHiA GENETICS SA has a 52 week low of $2.96 and a 52 week high of $7.86. The company’s 50 day moving average price is $5.57 and its 200 day moving average price is $5.13. The stock has a market capitalization of $646.79 million, a PE ratio of -6.70 and a beta of 0.96. The company has a quick ratio of 1.90, a current ratio of 2.69 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. Sell-side analysts forecast that SOPHiA GENETICS SA will post -0.58 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently bought and sold shares of the stock. 1492 Capital Management LLC purchased a new position in SOPHiA GENETICS in the 4th quarter worth approximately $973,000. Royce & Associates LP purchased a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at approximately $2,009,000. Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS in the first quarter worth approximately $2,157,000. Royal Bank of Canada grew its holdings in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares during the last quarter. Finally, Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS in the first quarter worth $1,772,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: BTIG Research raised its price target for SOPH from $8 to $9 while maintaining a Buy rating. The move adds to recent analyst support and reinforces the stock’s upward momentum. BTIG Research raises SOPHiA GENETICS price target
• Positive Sentiment: SOPHiA GENETICS reached a new 12-month high following the analyst upgrade, indicating strong investor demand and a favorable near-term trading reaction. SOPHiA GENETICS reaches a new 12-month high
• Positive Sentiment: HC Wainwright continues to rate SOPH Buy with a $14 price target, well above recent trading levels. Its longer-term forecast still calls for a return to profitability, including positive EPS estimates for 2029 and 2030.
• Neutral Sentiment: Chief Technology Officer Abhimanyu Verma sold 5,000 shares for approximately $34,750 under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance and reduced his ownership by only 2.6%, it carries limited signaling value.
• Negative Sentiment: HC Wainwright lowered EPS estimates across several periods: Q3 2026 to $(0.13), FY2026 to $(0.77) from $(0.58), FY2027 to $(0.31) from $(0.20), and FY2028 to $(0.02) from positive $0.04. Estimates for Q1–Q4 2027 were also reduced, suggesting profitability may arrive later than previously expected.
• Negative Sentiment: The company’s latest quarterly loss of $(0.26) per share exceeded the expected $(0.21) loss, highlighting ongoing profitability pressure despite revenue exceeding expectations. SOPH remains deeply unprofitable, which could limit further gains if growth or the path to breakeven weakens.

Wall Street Analyst Weigh In

SOPH has been the subject of several research reports. BTIG Research upped their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday. HC Wainwright lifted their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.